NUBEQA 300 mg film-coated tablets

A Multi-arm, Open-label Phase I/IIa Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of AZD5305 in Combination with New Hormonal Agents in Patients with Metastatic Prostate Cancer (PETRANHA)

Clinical Application of the Androgen Receptor Inhibitor Darolutamide to Upregulate the Prostate-Specific Membrane Antigen (PSMA) Protein Expression in Patients with Hormone Sensitive Prostate Cancer. - The DARO-flare Trial -

START : A randomized phase 2 study in patients with triple-negative, androgen receptor positive locally recurrent (unresectable) or metastatic breast cancer treated with darolutamide or capecitabine

A randomized phase II trial of docetaxel or cabazitaxel with or without darolutamide in men with metastatic castration-resistant prostate cancer.

Prostate Androgen Response Investigation using a Stratification BIOmarker - PARIS-BIO Predicting prostate cancer downstageing by neoadjuvant Darolutamide with PCAI ImmunoScore in a non-randomised open label prospective trial.

Metastasis-directed therapy in oligoprogressive castration-refractory prostate cancer: a randomized phase 3 trial

A randomised, phase 3 trial comparing 3-weekly docetaxel 75 mg/m2 (in a 3 week cycle) versus 2-weekly Docetaxel 50 mg/m2 (in a 4 week cycle) in combination with Darolutamide + ADT in patients with metastatic hormone sensitive prostate cancer (mHSPC)

A Randomized, 2-cohort, Double-blind, Placebo-controlled, Phase III Study of Saruparib (AZD5305) in Combination with Physician’s Choice New Hormonal Agents in Patients with HRRm and non-HRRm Metastatic Castration-Sensitive Prostate Cancer (EvoPAR-Prostate01).

PEACE 8: Combination of darolutamide and stereotactic body radiation therapy in patients with castration resistant prostate cancer and oligometastases on functional imaging.

ProBio: An outcome-adaptive and randomised multi-arm biomarker driven study in patients with metastatic prostate cancer